Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON ...

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Beam Therapeutics (BEAM) announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Beam Therapeutics Inc . (NASDAQ:BEAM), a $2.1 billion market cap pioneer in the field of precision genetic medicines through base editing, is set to present new data from its ongoing BEACON Phase 1/2 ...

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...